Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022
Background: Cervical cancer is the only cancer that can be eliminated worldwide. Tracking the latest burden of cervical cancer is critical toward the targets set by World Health Organization (WHO) to eliminate cervical cancer as a major public health problem. Methods: All data were extracted from th...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005425000134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839650245916491776 |
|---|---|
| author | Jie Wu Qianyun Jin Yunmeng Zhang Yuting Ji Jingjing Li Xiaomin Liu Hongyuan Duan Zhuowei Feng Ya Liu Yacong Zhang Zhangyan Lyu Lei Yang Yubei Huang |
| author_facet | Jie Wu Qianyun Jin Yunmeng Zhang Yuting Ji Jingjing Li Xiaomin Liu Hongyuan Duan Zhuowei Feng Ya Liu Yacong Zhang Zhangyan Lyu Lei Yang Yubei Huang |
| author_sort | Jie Wu |
| collection | DOAJ |
| description | Background: Cervical cancer is the only cancer that can be eliminated worldwide. Tracking the latest burden of cervical cancer is critical toward the targets set by World Health Organization (WHO) to eliminate cervical cancer as a major public health problem. Methods: All data were extracted from the Global Cancer Observatory (GLOBOCAN) 2022. Age-standardized incidence rate (ASIR) and mortality rates (ASMR) of cervical cancer were compared and linked to Human Development Index (HDI) between populations. The estimated annual percentage changes (EAPCs) were used to characterize the temporal trend in ASIR/ASMR, and demographic estimates were projected up to 2050. Results: Globally, an estimated 662,044 cases (ASIR: 14.12/100,000) and 348,709 deaths (ASMR: 7.08/100,000) from cervical cancer occurred in 2022, corresponding to the fourth cause of cancer morbidity and mortality in women worldwide. Specifically, 42 % of cases and 39 % of deaths occurred in China (23 % and 16 %) and India (19 % and 23 %). Both ASIR and ASMR of cervical cancer decreased with HDI, and similar decreasing links were observed for both early-onset (0–39 years) and late-onset (≥40 years) cervical cancer. Both ASIR and ASMR of overall cervical cancer showed decreasing trends during 2003–2012 (EAPC: 0.04 % and -1.03 %); however, upward trends were observed for early-onset cervical cancer (EAPC: 1.16 % and 0.57 %). If national rates in 2022 remain stable, the estimated cases and deaths from cervical cancer are projected to increase by 56.8 % and 80.7 % up to 2050. Moreover, the projected increase of early-onset cervical cancer is mainly observed in transitioning countries, while decreased burden is expected in transitioned countries. Conclusions: Cervical cancer remains a common cause of cancer death in many countries, especially in transitioning countries. Unless scaling-up preventive interventions, human papillomavirus (HPV) vaccination and cervical cancer screening, as well as systematic cooperation within government, civil societies, and private enterprises, the global burden of cervical cancer would be expected to increase in the future. |
| format | Article |
| id | doaj-art-2dedfa6b8e564d0e8be2f413e8606e8a |
| institution | Matheson Library |
| issn | 2667-0054 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj-art-2dedfa6b8e564d0e8be2f413e8606e8a2025-06-27T05:52:28ZengElsevierJournal of the National Cancer Center2667-00542025-06-0153322329Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022Jie Wu0Qianyun Jin1Yunmeng Zhang2Yuting Ji3Jingjing Li4Xiaomin Liu5Hongyuan Duan6Zhuowei Feng7Ya Liu8Yacong Zhang9Zhangyan Lyu10Lei Yang11Yubei Huang12Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaDepartment of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & Institute, Beijing, China; Corresponding authors.Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Human Major Diseases, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China; Corresponding authors.Background: Cervical cancer is the only cancer that can be eliminated worldwide. Tracking the latest burden of cervical cancer is critical toward the targets set by World Health Organization (WHO) to eliminate cervical cancer as a major public health problem. Methods: All data were extracted from the Global Cancer Observatory (GLOBOCAN) 2022. Age-standardized incidence rate (ASIR) and mortality rates (ASMR) of cervical cancer were compared and linked to Human Development Index (HDI) between populations. The estimated annual percentage changes (EAPCs) were used to characterize the temporal trend in ASIR/ASMR, and demographic estimates were projected up to 2050. Results: Globally, an estimated 662,044 cases (ASIR: 14.12/100,000) and 348,709 deaths (ASMR: 7.08/100,000) from cervical cancer occurred in 2022, corresponding to the fourth cause of cancer morbidity and mortality in women worldwide. Specifically, 42 % of cases and 39 % of deaths occurred in China (23 % and 16 %) and India (19 % and 23 %). Both ASIR and ASMR of cervical cancer decreased with HDI, and similar decreasing links were observed for both early-onset (0–39 years) and late-onset (≥40 years) cervical cancer. Both ASIR and ASMR of overall cervical cancer showed decreasing trends during 2003–2012 (EAPC: 0.04 % and -1.03 %); however, upward trends were observed for early-onset cervical cancer (EAPC: 1.16 % and 0.57 %). If national rates in 2022 remain stable, the estimated cases and deaths from cervical cancer are projected to increase by 56.8 % and 80.7 % up to 2050. Moreover, the projected increase of early-onset cervical cancer is mainly observed in transitioning countries, while decreased burden is expected in transitioned countries. Conclusions: Cervical cancer remains a common cause of cancer death in many countries, especially in transitioning countries. Unless scaling-up preventive interventions, human papillomavirus (HPV) vaccination and cervical cancer screening, as well as systematic cooperation within government, civil societies, and private enterprises, the global burden of cervical cancer would be expected to increase in the future.http://www.sciencedirect.com/science/article/pii/S2667005425000134Cervical cancerIncidenceMortalityTemporal trendFuture projection |
| spellingShingle | Jie Wu Qianyun Jin Yunmeng Zhang Yuting Ji Jingjing Li Xiaomin Liu Hongyuan Duan Zhuowei Feng Ya Liu Yacong Zhang Zhangyan Lyu Lei Yang Yubei Huang Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022 Journal of the National Cancer Center Cervical cancer Incidence Mortality Temporal trend Future projection |
| title | Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022 |
| title_full | Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022 |
| title_fullStr | Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022 |
| title_full_unstemmed | Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022 |
| title_short | Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022 |
| title_sort | global burden of cervical cancer current estimates temporal trend and future projections based on the globocan 2022 |
| topic | Cervical cancer Incidence Mortality Temporal trend Future projection |
| url | http://www.sciencedirect.com/science/article/pii/S2667005425000134 |
| work_keys_str_mv | AT jiewu globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT qianyunjin globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT yunmengzhang globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT yutingji globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT jingjingli globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT xiaominliu globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT hongyuanduan globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT zhuoweifeng globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT yaliu globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT yacongzhang globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT zhangyanlyu globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT leiyang globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 AT yubeihuang globalburdenofcervicalcancercurrentestimatestemporaltrendandfutureprojectionsbasedontheglobocan2022 |